BBIO

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio has built a diversified portfolio of over 20 development programs ranging from early science to advanced clinical trials. The company's strategy involves identifying promising therapeutic targets with genetic validation, rapidly advancing drug candidates through development, and partnering with leading academic institutions and biotechnology companies. BridgeBio's lead commercial product is Attruby (acoramidis), approved by the FDA for treating transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and fatal disease affecting the heart. The company's pipeline includes programs targeting various genetic diseases including achondroplasia (the most common form of dwarfism), cardiovascular conditions, oncology indications, and rare metabolic disorders. BridgeBio operates through a network of subsidiary companies, each focused on specific therapeutic areas or drug programs. The company's business model emphasizes genetic validation of drug targets, rapid development timelines, and strategic partnerships to maximize the probability of success and efficient capital deployment. BridgeBio has established collaborations with pharmaceutical companies and research institutions worldwide to accelerate development and expand commercial reach for its innovative therapies.